Platform expansion

About Viracta Therapeutics

Viracta Therapeutics is pioneering a precision oncology approach to treat virus-associated cancers, with a primary focus on Epstein-Barr virus (EBV)-positive malignancies. The company's proprietary platform combines a viral activator with targeted anticancer agents to selectively induce viral lytic activation in cancer cells. Its lead candidate, nanatinostat in combination with valganciclovir, is in late-stage development for EBV-positive lymphomas and nasopharyngeal carcinoma. Viracta aims to address significant unmet medical needs in oncology through its novel mechanism of action.

Therapeutic Areas